Bausch Health authorizes up to $50 million share repurchase program
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
What happened
Bausch Health's Board of Directors authorized a share repurchase program for its common shares. The program allows the company to purchase shares for a total aggregate price of up to US$50 million. Purchases may begin on November 3, 2026, and must conclude by November 3, 2027, on the New York Stock Exchange and other US markets.
From prnewswire.com
Why it matters
The primary objective of the program is to manage the potential dilutive impact of future employee equity-based compensation. The company will not repurchase more than 5% of the currently outstanding shares, and purchases will be made at the prevailing market price.
From prnewswire.com
Who's involved
- Bausch HealthThe company authorizing the share repurchase program.
- New York Stock ExchangeThe stock exchange where the share repurchases will take place.
Keep exploring
The entities involved
-
Bausch Health
multinational specialty drugs company based in Laval, Quebec, Canada
-
New York Stock Exchange
American stock exchange
Related events
- AstraZeneca listed shares on the New York Stock Exchange to attract investors.
- Harry Dietz and Tony Wood acquired shares via dividend reinvestment and purchased ADSs on the New York Stock Exchange.
- Kraft Heinz is planning to transfer its listing from Nasdaq to the NYSE, accompanied by SEC filings regarding ownership changes.
- West Pharmaceutical Services was reported to be traded on the New York Stock Exchange (NYSE) on October 19, 2026.
- A fund maintains its ticker symbol on the New York Stock Exchange.